Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc will present data from its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute Fall Congress from November 5-8, 2026. The data will include findings related to LYBALVI®, ARISTADA®, LUMRYZ®, and the novel investigational drug alixorexton. This event highlights Alkermes' ongoing research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes will present new data at a prominent congress.
  • Research includes multiple products from their portfolios.
  • The event will take place in a well-known location.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
3.1%
average across 10 past catalysts
Lead asset
ALKS 7290
Phase 2 · Attention Deficit Disorder With Hyperactivity (ADHD)

Full Press Release Details

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil) and LUMRYZ® (sodium oxybate) extended-release oral suspension, as well as alixorexton, the company’s novel, investigation

Frequently Asked Questions

What is the NEI Fall Congress?

The NEI Fall Congress is an event focused on neuroscience education.

When will Alkermes present at the congress?

Alkermes will present from November 5-8, 2026.

Which products will Alkermes present data on?

Alkermes will present data on LYBALVI®, ARISTADA®, and LUMRYZ®.

Where is the NEI Fall Congress held?

The congress will take place in Colorado Springs, Colorado.

ShareAdd on Google
Tags: ALKS Alkermes LYBALVI ARISTADA LUMRYZ neuroscience
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$787M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALKS 7290Phase 2
Attention Deficit Disorder With Hyperactivity (ADHD) →

Catalyst track record

+34%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →